Validation of Whole Body PET/CT Foundation Model
Prospective Multicenter Validation of Whole Body PET/CT Foundation Model for Bone Lesion Detection
1 other identifier
observational
180
0 countries
N/A
Brief Summary
Prospective multicenter study to validate the diagnostic performance of whole body PET/CT foundation model for bone lesion detection
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2025
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 20, 2025
CompletedFirst Posted
Study publicly available on registry
September 29, 2025
CompletedStudy Start
First participant enrolled
October 16, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 15, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 15, 2026
October 3, 2025
September 1, 2025
11 months
September 20, 2025
September 29, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Diagnostic performance (benign or malignant)
Patient based bone lesion diagnostic performance (benign or malignant)
At diagnosis time
Secondary Outcomes (4)
Diagnostic performance (primary or metastases)
At diagnosis time
Pathology prediction
At diagnosis time
Gene prediction
At diagnosis time
Prognosis prediction
At diagnosis time
Study Arms (2)
Group PET/CT
Whole body PET/CT foundation model
Group CT
Whole body CT foundation model
Eligibility Criteria
With suspicious lesion in the bone
You may qualify if:
- With suspicious lesion in the bone or with elevated serum tumor markers or patient insist
- Over 18 years
You may not qualify if:
- Active infection at or adjacent to the puncture site
- Severe coagulation disorders that cannot be corrected
- Random blood glucose \> 11.1 mmol/L
- Refuse for pathological confirmation or follow-up
- Extremely debilitated patients or those unable to cooperate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
September 20, 2025
First Posted
September 29, 2025
Study Start
October 16, 2025
Primary Completion (Estimated)
September 15, 2026
Study Completion (Estimated)
December 15, 2026
Last Updated
October 3, 2025
Record last verified: 2025-09